Neurocrine Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary

• Neurocrine Biosciences Inc NBIX.OQ reported quarterly adjusted earnings of 8 cents​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of 42 cents. The mean expectation of twenty four analysts for the quarter was for earnings of 54 cents per share. Wall Street expected results to range from -30 cents to $1.30 per share.

• Revenue rose 11.1% to $572.60 million from a year ago; analysts expected $559.33 million.

• Neurocrine Biosciences Inc's reported EPS for the quarter was 8 cents​.

• The company reported quarterly net income of $7.9 million.

• Neurocrine Biosciences Inc shares had fallen by 0.8% this quarter and lost 19.6% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 57.4% in the last three months.​

• In the last 30 days, eleven analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 21 "strong buy" or "buy," 5 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for Neurocrine Biosciences Inc is $160.00

This summary was machine generated from LSEG data May 5 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)